Morgan Stanley Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)
Morgan Stanley analyst Judah Frommer has reaffirmed a Hold rating on 4D Molecular Therapeutics (FDMT), with shares closing at $10.17. The analyst consensus for the stock is Strong Buy, with a price target of $34.43, indicating a potential upside of 238.54%. Another report from TR | OpenAI also maintained a Hold rating with a price target of $10.50. Frommer has an average return of 0.9% and a 55.02% success rate on his stock recommendations.
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Hold rating on 4D Molecular Therapeutics. The company’s shares closed yesterday at $10.17.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Zenas BioPharma, Inc., and Celldex. According to TipRanks, Frommer has an average return of 0.9% and a 55.02% success rate on recommended stocks.
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.43, implying a 238.54% upside from current levels. In a report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $10.50 price target.
